英菲格拉替尼Truseltiq治疗胆管癌效果显著

Cholangiocarcinoma refers to a malignant tumor originating from the extrahepatic bile duct, including the bile duct from the portal area to the lower end of the common bile duct. Its etiology may be related to bile duct stones, primary sclerosing cholangitis and other diseases. Its clinical manifestations include: jaundice, abnormal bowel movements, gallbladder enlargement, liver damage, biliary infection, biliary bleeding, etc. Surgery and chemotherapy are the main treatments for cholangiocarcinoma, but most patients are already in the intermediate and advanced stages when discovered, and the prognosis is extremely poor. Patients can choose to use it for treatment.

What is Truseltiq?

Infigratinib Truseltiq is an orally administered selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma.

Infigratinib Truseltiq mainly targets cholangiocarcinoma with FGFR2 fusion gene mutations. It induces tumor cell death by reducing cancer cell proliferation, which can bring benefits in progression-free survival and overall response rate.

How to use Truseltiq

The recommended dose of Infigratinib Truseltiq is: 125 mg, taken orally once a day, with 21 consecutive days of medication and 7 days of drug withdrawal, with a 28-day treatment cycle. It is best to take this medicine at the same time every day, at least 1 hour before or 2 hours after meals, on an empty stomach. Patients should be careful when taking this drug: they should swallow the entire capsule with a glass of water and do not crush, chew or dissolve the capsule before taking it. Also, you should not eat grapefruit or drink grapefruit juice while being treated with this medicine.

Infigratinib and Truseltiq are effective in treating cholangiocarcinoma

A phase 2, multicenter, single-arm clinical study evaluated infigratinib as third-line or higher treatment for patients with FGFR2 fusion-positive cholangiocarcinoma.

A total of 71 patients were included in the trial, and all patients were treated according to the recommended dose of Truseltiq infigratinib until disease progression or unacceptable toxicity.

The trial results showed that in the second-line treatment, the median progression-free survival (PFS) of the patients was 4.63 months; in the third-line or above, the median progression-free survival (PFS) of the patients treated with infigratinib was 6.77 months. In patients who received third or higher lines of therapy, the objective response rate (ORR) of Truseltiq was 21.6%.

It can be concluded that in patients with cholangiocarcinoma with FGFR2 fusion, infigratinib Truseltiq in third-line and above-line treatment has greater benefits in terms of objective response rate (ORR) and progression-free survival (PFS) compared with second-line standard chemotherapy regimen. Infigratinib can relieve patients' pain and have a positive effect on the patient's condition. The launch of this drug has brought new treatment options and options to patients with cholangiocarcinoma.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: